| Trial ID: | L0323 |
| Source ID: | NCT05195944
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Semaglutide vs Sitagliptin
|
| Acronym: |
--
|
| Status: |
Not yet recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Liver Transplant; Complications|Diabetes Mellitus|NASH - Nonalcoholic Steatohepatitis|NAFLD
|
| Interventions: |
Drug: Semaglutide Treatment|Drug: Sitagliptin 100mg
|
| Outcome Measures: |
Change in HbA1c level (%)|Change in body weight (kg)|Number of treatment-emergent adverse events
|
| Sponsor/Collaborators: |
University Health Network, Toronto|Novo Nordisk A/S
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
140
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
April 2022
|
| Completion Date: |
December 2024
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 19, 2022
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT05195944
|
